

SCIENTIFIC DIRECTOR

Dr. UGO DE GIORGI

Director Genitourinary Oncology Department
Istituto Scientifico Romagnolo per lo Studio e la
Cura dei Tumori (IRST) - IRCCS Meldola (FC)

SCIENTIFIC COORDINATOR

Dr. Vincenza Conteduca

Oncology Department
IRCSS-IRST and ICR London

FACULTY

GERHARDT ATTARD

London - UK

UMBERTO BASSO

Padua - I

ELENA CASTRO

Madrid - E

VINCENZA CONTEDEUCA

Meldola - I

PAOLO CREMASCHI

London - UK

UGO DE GIORGI

Meldola - I

ENRIQUE GONZALEZ-BILLALABEITIA

Murcia - E

DAVID OLMOS

Madrid - E

GIOVANNI PAGANELLI

Meldola - I

ALISON REID

London - UK

ALESSANDRO ROMANEL

Trento - I

SAMANTA SALVI

Meldola - I

ANJUI WU

London - UK

VENUE

Istituto Scientifico Romagnolo
per lo Studio e la Cura dei Tumori (IRST)
via Piero Maroncelli, 40
47014 Meldola (FC)

REGISTRATION

Registration is free of charge and
has to be done online from the
website www.mitcongressi.it
section: **BIOMARKERS SUMMIT IN
UROLOGICAL CANCERS**

CME

5 CME has been requested for the
following professional figures:
Pathologist, Pharmacologist, Genetist,
Genetist for Medical Laboratory,
Nuclear Physician, Oncologist,
Radiotherapist, Urologist, Pharmacist,
Psychologist, Biomedical Laboratory
Technician, Biologist, Nurse

MEETING SECRETARIAT



MI&T Srl Viale Carducci, 50
40125 Bologna - Tel. 051 220427
info@mitcongressi.it
www.mitcongressi.it

BIOMARKERS SUMMIT IN UROLOGICAL CANCERS INTERNATIONAL CONFERENCE

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
NOVEMBER 3, 2017 MELDOLA ITALY



UNRESTRICTED GRANT BY

platinum



gold



Bristol-Myers Squibb

janssen Oncology

PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Pfizer Oncology

silver



SANOFI GENZYME



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Istituto di Ricovero e Cura a Carattere Scientifico



The purpose of this international meeting is to focus on the state of the art on the use of biomarkers in prostate cancer, analyzing the recent research acquisitions in this field and evaluating future development strategies to better integrate the laboratory and clinic in these tumors. The conference is addressed to biologists with interest in biomarkers and on prostate cancer and clinical oncologists, radiotherapists, nuclear physicians and urologists, pharmacists.



- 8.30 Registration
- 9.00 **Introduction and presentation**
IRST IRCCS Scientific Director
and U. De Giorgi, Head GU Unit

1st SESSION

HETEROGENEITY OF PROSTATE CANCER TREATMENT SELECTION FROM EARLY TO ADVANCED DISEASE

Moderators: U. De Giorgi, G. Paganelli

- 9.30 **Precision medicine of not previously treated patients with hormone therapy**
G. Attard
- 9.50 **AR-pathway inhibitors in CRPC: where do we stand in 2017?**
D. Olmos
- 10.10 **Radium-223 in metastatic prostate cancer patients**
V. Conteduca
- 10.30 **¹⁷⁷Lu PSMA 617: a new way in prostate cancer patients?**
G. Paganelli
- 10.50 **Discussion on the topics discussed**
- 11.10 Coffee break

2nd SESSION

BIOMARKERS IN PROSTATE CANCER NEW CHALLENGES IN CLINICAL APPLICATION

Moderators: G. Attard, E. Castro

- 11.30 **Exploring biomarkers in prostate cancer on the basis of RNA expression profiling**
P. Cremaschi
- 11.50 **A new approach to evaluating aberrant DNA methylation profiles**
A. Wu
- 12.10 **Polymorphisms in non-coding regulatory genes in prostate cancer**
A. Romanel
- 12.30 **Inherited alterations in DNA repair genes: cancer risk and therapeutic implications**
E. Castro
- 12.50 **Discussion on the topics discussed**
- 13.10 Lunch

3rd SESSION

BIOMARKERS IN UROLOGICAL CANCER

Moderators: E. Gonzalez-Billalabeitia, A. Reid

- 14.10 **Immunotherapy: a new treatment paradigm in bladder cancer**
E. Gonzalez-Billalabeitia
- 14.30 **The changing therapeutic landscape of kidney cancer**
U. Basso
- 14.50 **The potential role of circulating PD-1/PD-L1 in urological tumors**
S. Salvi
- 15.10 **An overview of genetics and potential biomarkers for outcome of germ cell tumors**
A. Reid
- 15.30 **Discussion on the topics discussed**
- 16.00 **Conclusions**
- 16.30 CME test